Your session is about to expire
← Back to Search
EYP-1901 for Wet Age-Related Macular Degeneration (DAVIO2 Trial)
DAVIO2 Trial Summary
This trial is testing a new drug, EYP-1901, to see if it is better than Aflibercept at treating wet age-related macular degeneration.
DAVIO2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDAVIO2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 26 Patients • NCT03022292DAVIO2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any eye conditions like cataract or glaucoma in the study eye.I have been diagnosed with wet age-related macular degeneration in one eye.I've had at least two eye injections for wet AMD in the last 6 months.I have had or currently have eye inflammation, not from cataract surgery.
- Group 1: EYP-1901 2060 ug
- Group 2: EYP-1901 3090 ug
- Group 3: Aflibercept
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the total number of participants being recruited for this trial?
"Indeed, the clinical trial is still actively recruiting. The study was first advertised on 28th July 2022 and modified 18th August 2022. 150 patients need to be enrolled from 4 different research centres."
Has Eyp-1901 received approval from the U.S. Food and Drug Administration?
"Due to limited clinical evidence of efficacy, Eyp-1901 was assigned a safety rating of 2. Nonetheless, there is some data confirming its security profile."
Are there numerous healthcare facilities in North America conducting this experiment?
"This experiment is currently being conducted at 4 distinct medical centres situated in Austin, Dallas and San Antonio amongst others. To make the process more convenient for participants, it's recommended to pick a clinic close by."
Are individuals still eligible to volunteer for this experiment?
"Indeed, the clinicaltrials.gov website implies that this trial is presently looking for volunteers. Having first been uploaded on July 28th 2022, it has recently undergone a revision and seeks to enrol 150 participants from 4 sites."
Share this study with friends
Copy Link
Messenger